Lucy Therapeutics appoints Dr Julia Gaebler as Chief Business Officer

Private biotech company Lucy Therapeutics, Inc. has announced the appointment of business-side biopharma leader Julia Gaebler, Ph.D., as Chief Business Officer (CBO).

Dr Gaebler has more than 25 years of business development and strategy experience in the life sciences industry, spanning biopharma, consulting and academia.

The new CBO will direct Lucy Therapeutics’ fundraising, growth and partnership activities for its proprietary preclinical compounds in Parkinson’s disease, Rett syndrome and other diseases of mitochondrial dysfunction.

Amy Ripka, Ph.D., CEO and founder of Lucy Therapeutics, said:

“As we grow Lucy Therapeutics, the in-house expertise Julia brings will be vital to our success.

“Her diverse business skills, can-do attitude and neurology background are tremendous assets that will help build our team as we embark on the next phase of our drug discovery and development.”

Dr Gaebler has more than two decade of experience in in-house and consulting positions with life science startups, and small and large pharma companies across numerous therapeutic areas including CNS, cardiometabolic, infectious diseases, and orphan conditions.

Prior to joining Lucy Therapeutics, Dr Gaebler held the role of vice president of commercial strategy and portfolio planning at Milestone Pharmaceuticals and partner at Health Advances, a life-sciences strategy consulting firm.

She has also held positions at the likes of Hoffmann-La Roche, Amylin and Biogen, where she managed the global market access launches for FAMPRYA and TECFIDERA, both indicated for patients with multiple sclerosis.

Dr Gaebler said:

“Joining the talented and passionate people at Lucy Therapeutics is an opportunity to collaborate on the promising, novel search for much needed therapies that can halt, if not reverse, devastating CNS diseases.

“I look forward to offering my corporate and business development experience to support Lucy Therapeutics’ focus on mitochondrial dysfunction as a nexus of biological paths contributing to the development of diseases such as Parkinson’s and Rett syndrome.”